TrialVaccine2022

Safety and immunogenicity of NVX-CoV2373 (TAK-019) vaccine in healthy Japanese adults: Interim report of a phase I/II randomized controlled trial.

Taisei Masuda et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.